Amarin (AMRN) Delays Hiring Vascepa Sales Reps Until Early December

Go back to Amarin (AMRN) Delays Hiring Vascepa Sales Reps Until Early December

Amarin (AMRN) Still Risky into NCE Amid Vascepa Sales Staff Additions, Financing - Analyst

December 7, 2012 7:20 AM EST

Amarin (Nasdaq: AMRN) is in the dumps Friday morning following a news release Thursday night that it was entering a non-equity financing agreement for $100 million and hiring about 250 to 300 reps for its Vascepa launch.

Today, Wedbush is out with some comments on the news today.

Wedbush said the timing of the release was a surprise following... More

Amarin (AMRN) Vascepa Pricing Leak?

December 3, 2012 3:21 PM EST

Amarin Corp Plc (NASDAQ: AMRN) investors were buzzing earlier today after a website inadvertently posted prices for Vascepa that appeared to be relatively low compared to market expectations.

GoodRx was showing prices of $51 for 30 capsules of 1g Vascepa (see below), although... More

Speculation Heats Up on Amarin (AMRN) After Sales Force Hiring Delayed

November 29, 2012 8:54 AM EST

Amarin Corp Plc (NASDAQ: AMRN) is higher early Thursday amid news the company is delaying the hiring of a sales force until December versus November.

While on the surface this news would seem neutral-to-negative, speculators view this as an indications that... More